# US 2024/0254248 A1 · Cd40 antibody pharmaceutical composition and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254248 A1
- Document ID: US20240254248A1
- Status: Published application
- Kind: A1
- Application number: 17/298,414
- Filed: 2019-11-29
- Published: 2024-08-01
- Earliest claimed: 2018-11-30
- Assignees: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.
- Applicants: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.
- Inventors: Jianjian YANG; Hao LI; Xun LIU; Jiahua JIANG
- Web page: https://patentgrep.com/patent/US20240254248A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical composition comprising a CD40 antibody or an antigen-binding fragment thereof and an acetic acid-sodium acetate buffer solution, and a use thereof. The pharmaceutical composition may further contain sugar, a non-ionic surfactant, and other excipients. The pharmaceutical composition of the present invention shows good antibody stability.

## Claims

### Claim 1

A pharmaceutical composition comprising a CD40 antibody or an antigen-binding fragment thereof, and a buffer, wherein the CD40 antibody or the antigen-binding fragment thereof has LCDR1, LCDR2 and LCDR3 respectively shown in SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, and HCDR1, HCDR2 and HCDR3 respectively shown in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the CD40 antibody or the antigen-binding fragment thereof has a concentration of 1 mg/ml to 120 mg/ml.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition has a pH of 4.5 to 6.5.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the buffer has a concentration of 5 mM to 30 mM.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, which further comprises a disaccharide selected from trehalose and sucrose.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the disaccharide has a concentration of 40 mg/ml to 95 mg/ml.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, which further comprises a surfactant that is polysorbate.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the surfactant has a concentration of 0.02 mg/ml to 0.8 mg/ml.

### Claim 9

A pharmaceutical composition comprising:
(a) 1 to 120 mg/ml of a CD40 antibody or an antigen-binding fragment thereof, wherein the CD40 antibody or the antigen-binding fragment thereof has LCDR1, LCDR2 and LCDR3 shown in SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively, and HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively,
(b) 5 to 30 mM of acetate buffer,
(c) 40 to 90 mg/ml of sucrose,
(d) 0.02 to 0.8 mg/ml of polysorbate 80.

### Claim 10

A pharmaceutical composition comprising:
(a) 1 to 120 mg/ml of a CD40 antibody or an antigen-binding fragment thereof, wherein the CD40 antibody or antigen-binding fragment thereof has LCDR1, LCDR2 and LCDR3 respectively shown in SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, and HCDR1, HCDR2 and HCDR3 respectively shown in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, and
(b) 10 to 20 mM acetate buffer, and the pharmaceutical composition has a pH of 5.0 to 5.5.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the CD40 antibody or the antigen-binding fragment thereof has a heavy chain variable region shown in SEQ ID NO: 1, and a light chain variable region shown in SEQ ID NO: 2.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the CD40 antibody or the antigen-binding fragment thereof is a humanized antibody.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein light chain FR sequences on the light chain variable region and heavy chain FR sequences on the heavy chain variable region of the humanized antibody are respectively derived from human germline light chain and heavy chain, or mutant sequences thereof.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein heavy chain of the humanized antibody has a sequence shown in SEQ ID NO: 17 or a variant thereof; wherein light chain of the humanized antibody has a sequence shown in SEQ ID NO: 18 or a variant thereof.

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein the heavy chain variable region of the humanized antibody further comprises heavy chain FRs of human IgG1, IgG2, IgG3 or IgG4 or a variant thereof.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein amino acid sequence of the light chain of the CD40 antibody has at least 90% sequence identity with sequence shown in SEQ ID NO: 18, amino acid sequence of the heavy chain of the antibody has at least 90% sequence identity with sequence shown in SEQ ID NO: 17.

### Claim 17 (depends on 1)

A method for preparing a lyophilized preparation comprising CD40 antibody, which comprises the step of lyophilizing the pharmaceutical composition of claim 1.

### Claim 18 (depends on 17)

A lyophilized preparation comprising CD40 antibody prepared by the method of claim 17.

### Claim 19 (depends on 1)

A method for treating diseases or symptoms, comprising administering the pharmaceutical composition of claim 1 to a subject in need thereof, wherein the diseases or symptoms are cancers.

### Claim 20 (depends on 1)

A product comprising a container, wherein the container contains the pharmaceutical composition of claim 1.
